Market News Latest

Creative Biolabs Offers Innovative Solutions for Complement Therapeutics

 Breaking News
  • No posts were found

Creative Biolabs Offers Innovative Solutions for Complement Therapeutics

November 21
14:39 2022
With years of experience in the development of complement therapeutics, Creative Biolabs is dedicated to offering novel solutions for researchers worldwide to advance research regarding complement therapeutics based on specific project needs.

New York, USA – November 21, 2022 – Complement-based drug discovery and development has received significant interest and attention from global scientists dedicated to studying complement therapeutics, which have dramatically expedited the development of complement therapeutics. In order to support relevant studies in this field, Creative Biolabs has enhanced its capacities in complement-based drug discovery and established an advanced drug discovery and development platform to provide comprehensive one-stop services for complement therapeutics.

Complement can be activated in three different ways, one of which is the classical pathway. The classical pathway for complement activation is a major contributor to the defense against infections, the removal of necrotic cells, and the maintenance of homeostasis. Creative Biolabs can provide custom services based on targets of the classical pathway and a full range of therapeutical antibodies, inhibitors, and soluble complement regulators, such as C1 inhibitors, C3 inhibitors, C5 inhibitors, and C5aR inhibitors.

“It is well known that the complement system functions as a ‘complement’ of the immune system, playing an important role in immune response, pathogen clearance, and inflammation,” according to a scientist at Creative Biolabs, “and the complement cascade cannot be activated without the catalysis of several enzymes, among which C3 convertase and C5 convertase are considered the most important ones.”

Indeed, C3 convertase and C5 convertase are both potential complement therapeutic targets in the treatment of related diseases, such as hemolytic uremic syndrome (HUS), which is induced by the down-regulation of C5 convertase blocking. With years of experience leading complement-based drug discovery and development, Creative Biolabs can assist researchers who are working with or getting prepared to work with C3 or C5 convertases for drug discovery and validation.

Furthermore, Creative Biolabs offers custom solutions and services based on the C5 convertase to meet specific demands from global clients, which mainly include verification of C5 convertase activity, C5 convertase deficiency identification, and C5 convertase inhibitor development.

To learn more about services regarding complement therapy at Creative Biolabs, please visit

About Creative Biolabs

Creative Biolabs is a biotech CRO company based in New York, United States, armed with a group of elite scientific minds and technicians that has been working in the development of complement therapeutics for several decades and has acquired enriched experience in providing high-quality complement therapy services. For decades, the company has kept its minds focused on becoming a dependable and high-tech biotech firm that contributes to the advancement of complement-based drug discovery.

Media Contact
Company Name: Creative Biolabs
Contact Person: Candy Swift
Email: Send Email
Phone: 1-631-830-6441
Country: United States